Pharmaron Beijing Co., Ltd. Class H (17Q1) AI Stock Analysis

0 Followers

Pharmaron Beijing Co., Ltd. Class H

(Frankfurt:17Q1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Revenue GrowthRobust multi-year and TTM revenue growth indicates continued demand for Pharmaron’s research, development, and manufacturing services. Sustained expansion can broaden customer relationships, improve operating scale, and support reinvestment across its integrated life-sciences platform over the next several quarters.

Negative Factors

Margin CompressionThe decline in net margin from roughly 22% to 11% shows that revenue growth has not translated into stable profitability at prior levels. Persistent compression would reduce earnings conversion, limit internal funding capacity, and make future growth less valuable if costs continue rising faster than revenue.

Pharmaron Beijing Co., Ltd. Class H (17Q1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 10.12B
Dividend Yield: 0.75%
Average Volume (3M): 1,112
Price to Earnings (P/E): 44.6
Beta (1Y): 0.78
Revenue Growth: 17.92%
EPS Growth: 14.10%
Country: Germany
Employees: 25,088
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Pharmaron Beijing Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory...

Pharmaron Beijing Co., Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:17Q1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2269	79Outperform	HKD 204.30B	34.83	10.51%	―	21.93%	21.94%
HK:1521	66Neutral	HKD 4.33B	51.11	3.02%	―	10.32%	178.23%
HK:1548	65Neutral	HKD 76.86B	-14.09	-16.23%	―	53.48%	-120.02%
HK:6821	55Neutral	HKD 61.98B	46.15	6.66%	1.21%	23.95%	18.73%
HK:1873	52Neutral	HKD 2.76B	13.52	4.45%	―	7.38%	7.90%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:17Q1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:17Q1	Pharmaron Beijing Co., Ltd. Class H	3.38	0.77	29.55%
HK:1548	Genscript Biotech Corporation	34.74	18.23	110.42%
HK:2269	Wuxi Biologics (Cayman)	48.88	14.40	41.76%
HK:1521	Frontage Holdings Corp.	2.10	1.01	92.20%
HK:1873	Viva Biotech Holdings	1.30	-0.88	-40.14%
HK:6821	Asymchem Laboratories (Tianjin) Co., Ltd. Class H	123.70	40.50	48.68%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pharmaron Beijing Co., Ltd. Class H AI Stock Analysis